abstract |
The present invention relates to a pharmaceutical composition comprising a 4-pregenen-11-17-21-triol-3,20-dione derivative, and as a pharmaceutical, a glucocorticoid receptor (GR) and / or a mineralcorticoid receptor (MR). It relates to use as a modifier. The present invention specifically relates to the use of these compounds and their pharmaceutical compositions for treating ophthalmic conditions associated with modulation of glucocorticoid receptor (GR) and / or mineralocorticoid receptor (MR). . [Selection figure] None |